

Creation of an innovative and attractive training programme for prescribers to promote the correct use of fluoroquinolones (FQ)


F.Théron (1), S.Carret (1), S.Ley (2), J.Y.Chastenet (3), S.Ousseini (1), J.Niel (1)

(1) Centre Hospitalier d'Ussel, Service Pharmacie, Ussel, France ; (2) Centre Hospitalier d'Ussel, Service Maladies Infectieuses, Ussel, France ; (3) Centre Hospitalier d'Ussel, Service Qualité et Gestion des risques, Ussel, France

OBJECTIVES

→ Innovative and attractive training programme for prescribers to promote the correct use of fluoroquinolones (FQ)

METHODS




RESULTS

TRAINING PROGRAMME

- ✓ The group session : **65% of participation**
 - ✓ E-learning : **7 physicians** (participated at all e-learning)
 - ✓ Evaluation (note):
- | | Before | After |
|----------------------|--------|-------|
| Group session (n=33) | 4/9 | 8/9 |
| E-learning | 6/10 | 8/10 |
- ✓ **Satisfaction** : 😊 All of participants found this training useful

Year	2014	2017
Duration (days)	43	77
Number of prescriptions	47	48

Percentages of conformity




Increase in the percentage of global conformity → improvement of practices

AUDITS

Increase in the duration of the 2017's audit compared to 2014's audit (for a similar number of prescriptions) → ↘ in the use of fluoroquinolones of 43% in 2017

Repartition of infections treated with FQ in the 2 audits



✓ ↘ low respiratory infection treated with FQ in 2017

✓ Appearance of osteo-articular system infection, bacteriemia, skin and soft tissues infections treated with FQ in 2017

CONCLUSIONS-DISCUSSION

- This initiative, conducted by a chemist, a physician specialized in infectious diseases and a quality expert, has led to the development of training for prescribers **combining traditional and digital tools**.
- Valorization in a "**Continuing Professional Development Programme**" is a real argument which attracts more participants and allows sustainability of this project.
- Furthermore, **the warning issued by the European Medicines Agency** of potentially permanent side effects of quinolone and fluoroquinolone antibiotics is an argument to pursue this training programme, in order to restrict the prescriptions.

ACKNOWLEDGEMENTS-REFERENCES

1. <https://www.ncbi.nlm.nih.gov/pubmed/?term=Relevance+of+Fluoroquinolone+Use+in+a+French+Teaching+Hospital>
2. <https://www.ncbi.nlm.nih.gov/pubmed/?term=Optimizing+Fluoroquinolone+Utilization+in+a+Public+Hospital+%3A+A+Prospective+Study+of+Educational+Intervention>
3. <https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products#key-facts-section>

